Literature DB >> 33306087

An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33306087     DOI： 10.1001/jama.2020.24415

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  25 in total

1.  Intravenous bamlanivimab use associates with reduced hospitalization in high-risk patients with mild to moderate COVID-19.

Authors:  Ravindra Ganesh; Colin F Pawlowski; John C O'Horo; Lori L Arndt; Richard F Arndt; Sarah J Bell; Dennis M Bierle; Molly Destro Borgen; Sara N Hanson; Alexander Heyliger; Jennifer J Larsen; Patrick J Lenehan; Robert Orenstein; Arjun Puranik; Leigh L Speicher; Sidna M Tulledge-Scheitel; A J Venkatakrishnan; Caroline G Wilker; Andrew D Badley; Raymund R Razonable
Journal:  J Clin Invest       Date:  2021-10-01       Impact factor: 14.808

2.  Evidence Based Scarce Resource Allocation During the COVID-19 Pandemic: A Case Study of Bamlanivimab Administration in the Emergency Department.

Authors:  Elizabeth Rozycki; Ashley Weiner; Carlos Malvestutto; Nicholas E Kman; Mark Lustberg; Michael Dick; K Joy Lehman; Ariane Schieber; Lynne Luca; Trisha A Jordan; Erica E Reed; James Allen; Jonathan Parsons; Courtney Nichols; Mark J Conroy
Journal:  Hosp Pharm       Date:  2022-02-02

3.  Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019.

Authors:  Raymund R Razonable; Ravindra Ganesh; Rachel K Bishop; Tracy L Culbertson; Molly Destro Borgen; Michelle C Hedin; Laura H Hopkins; Tammy A Jackson; Jennifer J Larsen; Jennifer A Matoush; Darcie E Moehnke; Shelly M Olson; Kellie M Peterson; Jordan Rosedahl; Lindsey M Philpot
Journal:  J Patient Exp       Date:  2022-06-23

4.  Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.

Authors:  Raymund R Razonable; John C O'Horo; Douglas W Challener; Lori Arndt; Richard F Arndt; Caroline G Clune; Tracy L Culbertson; Scott T Hall; Alexander Heyliger; Tammy A Jackson; Brian D Kennedy; Jennifer Larsen; Sara N Hanson; Perry W Sweeten; Sidna M Tulledge-Scheitel; Ravindra Ganesh
Journal:  Mayo Clin Proc       Date:  2022-06-23       Impact factor: 11.104

Review 5.  Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants.

Authors:  Cong Sun; Chu Xie; Guo-Long Bu; Lan-Yi Zhong; Mu-Sheng Zeng
Journal:  Signal Transduct Target Ther       Date:  2022-06-28

6.  A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model.

Authors:  Raymund R Razonable; Nicole C E Aloia; Ryan J Anderson; Gokhan Anil; Lori L Arndt; Richard F Arndt; Sara E Ausman; Sarah J Bell; Dennis M Bierle; Marcie L Billings; Rachel K Bishop; Carl H Cramer; Tracy L Culbertson; Ala S Dababneh; Amber N Derr; Kevin Epps; Susan M Flaker; Ravindra Ganesh; Mary A Gilmer; Eric Gomez Urena; Christopher R Gulden; Tamara L Haack; Sara N Hanson; Jenna R Herzog; Alexander Heyliger; Lex D Hokanson; Laura H Hopkins; Richard J Horecki; Bipinchandra Hirisave Krishna; W Charles Huskins; Tammy A Jackson; Ryan R Johnson; Betty Jorgenson; Cory Kudrna; Brian D Kennedy; Mary K Klingsporn; Brian Kottke; Jennifer J Larsen; Sarah R Lessard; Larry I Lutwick; Edward J Malone; Jennifer A Matoush; Ivana N Micallef; Darcie E Moehnke; Muhanad Mohamed; Colleena N Ness; Shelly M Olson; Robert Orenstein; Raj Palraj; Janki Patel; Damian J Paulson; David Phelan; Margaret T Peinovich; Wilford L Ramsey; Taunya J Rau-Kane; Kevin I Reid; Karen J Reinschmidt; Maria Teresa Seville; Erin C Skold; Jill M Smith; Leigh L Speicher; Laurie A Spielman; Donna J Springer; Perry W Sweeten; Jennifer M Tempelis; Sidna Tulledge-Scheitel; Paschalis Vergidis; Daniel C Whipple; Caroline G Wilker; Molly J Destro Borgen
Journal:  Mayo Clin Proc       Date:  2021-03-09       Impact factor: 7.616

7.  Practical recommendations for the prevention and management of COVID-19 in low-income and middle-income settings: adapting clinical experience from the field.

Authors:  Sasha Abdallah Fahme; Kathleen F Walsh; Vanessa Rouzier; Puja Chebrolu; Hyasinta Jaka; Justin Roy Kingery; Fouad M Fouad; Jyoti S Mathad; Jennifer A Downs; Margaret McNairy
Journal:  Fam Med Community Health       Date:  2021-04

Review 8.  The impact of COVID-19 on kidney transplantation and the kidney transplant recipient - One year into the pandemic.

Authors:  Pascale Khairallah; Nidhi Aggarwal; Ahmed A Awan; Chandan Vangala; Medha Airy; Jenny S Pan; Bhamidipati V R Murthy; Wolfgang C Winkelmayer; Venkat Ramanathan
Journal:  Transpl Int       Date:  2021-02-26       Impact factor: 3.842

9.  National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2-Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments.

Authors:  Joel M Gelfand; April W Armstrong; Stacie Bell; George L Anesi; Andrew Blauvelt; Cassandra Calabrese; Erica D Dommasch; Steven R Feldman; Dafna Gladman; Leon Kircik; Mark Lebwohl; Vincent Lo Re; George Martin; Joseph F Merola; Jose U Scher; Sergio Schwartzman; James R Treat; Abby S Van Voorhees; Christoph T Ellebrecht; Justine Fenner; Anthony Ocon; Maha N Syed; Erica J Weinstein; George Gondo; Sue Heydon; Samantha Koons; Christopher T Ritchlin
Journal:  J Am Acad Dermatol       Date:  2021-01-07       Impact factor: 15.487

10.  A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19.

Authors:  Michael A Puskarich; Nathan W Cummins; Nicholas E Ingraham; David A Wacker; Ronald A Reilkoff; Brian E Driver; Michelle H Biros; Fernanda Bellolio; Jeffrey G Chipman; Andrew C Nelson; Kenneth Beckman; Ryan Langlois; Tyler Bold; Matthew T Aliota; Timothy W Schacker; Helen T Voelker; Thomas A Murray; Joseph S Koopmeiners; Christopher J Tignanelli
Journal:  EClinicalMedicine       Date:  2021-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.